Engel, Kirsten Rita

[["dc.bibliographiccitation.firstpage","1163"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","1169"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Herchenhein, Thomas"],["dc.contributor.author","Kirchhainer, Julia"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:36:24Z"],["dc.date.available","2018-11-07T08:36:24Z"],["dc.date.issued","2010"],["dc.description.abstract","Alcohol addiction is associated with alterations of central nervous dopaminergic and serotonergic functions. Acute tryptophan depletion has not yet been applied in detoxified alcohol-addicted patients in order to investigate its impact on psychopathology, psychoneuroendocrinology, and substance craving behaviour. 25 alcohol-addicted males randomly either received a tryptophan-free or tryptophan-containing amino acid drink and 7 days later the respective other drink. Anxiety, depression, and craving were assessed before and 5 h after the drink. Tryptophan, 5-HIAA, dopamine, norepinephrine, epinephrine, and HVA in serum were measured before and after both treatments. Nocturnal urinary cortisol measurements and genotyping for the HTTLPR polymorphism of the SLC6A4 gene were performed. Tryptophan depletion resulted in a significant reduction of total and free serum tryptophan while the tryptophan-rich drink increased serum levels. Both treatments caused a significant increase of serum serotonin levels, however, serum 5-HIAA was decreased after depletion but increased after sham depletion. Dopamine and norepinephrine were elevated after tryptophan depletion and sham. Depletion increased depression scores (MADRS), while the full amino acid drink improved state and trait anxiety ratings (STAI) and substance craving. Urinary cortisol excretion was not affected by both treatments. Patients with the II genotype of the serotonin transporter gene displayed lower baseline tryptophan levels compared to patients with the heterozygous genotype. Results suggest an impaired serotonergic function in alcohol-addicted males. (C) 2010 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.jpsychires.2010.04.002"],["dc.identifier.isi","000285952000007"],["dc.identifier.pmid","20579662"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18303"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0022-3956"],["dc.title","Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","557"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","566"],["dc.bibliographiccitation.volume","266"],["dc.contributor.author","Engel, K. R."],["dc.contributor.author","Obst, K."],["dc.contributor.author","Bandelow, B."],["dc.contributor.author","Dechent, P."],["dc.contributor.author","Gruber, O."],["dc.contributor.author","Zerr, I."],["dc.contributor.author","Ulrich, K."],["dc.contributor.author","Wedekind, D."],["dc.date.accessioned","2017-11-28T10:03:35Z"],["dc.date.available","2017-11-28T10:03:35Z"],["dc.date.issued","2015"],["dc.description.abstract","There is evidence that besides limbic brain structures, prefrontal and insular cortical activations and deactivations are involved in the pathophysiology of panic disorder. This study investigated activation response patterns to stimulation with individually selected panic-specific pictures in patients with panic disorder with agoraphobia (PDA) and healthy control subjects using functional magnetic resonance imaging (fMRI). Structures of interest were the prefrontal, cingulate, and insular cortex, and the amygdalo-hippocampal complex. Nineteen PDA subjects (10 females, 9 males) and 21 healthy matched controls were investigated using a Siemens 3-Tesla scanner. First, PDA subjects gave Self-Assessment Manikin (SAM) ratings on 120 pictures showing characteristic panic/agoraphobia situations, of which 20 pictures with the individually highest SAM ratings were selected. Twenty matched pictures showing aversive but not panic-specific stimuli and 80 neutral pictures from the International Affective Picture System were chosen for each subject as controls. Each picture was shown twice in each of four subsequent blocks. Anxiety and depression ratings were recorded before and after the experiment. Group comparisons revealed a significantly greater activation in PDA patients than control subjects in the insular cortices, left inferior frontal gyrus, dorsomedial prefrontal cortex, the left hippocampal formation, and left caudatum, when PA and N responses were compared. Comparisons for stimulation with unspecific aversive pictures showed activation of similar brain regions in both groups. Results indicate region-specific activations to panic-specific picture stimulation in PDA patients. They also imply dysfunctionality in the processing of interoceptive cues in PDA and the regulation of negative emotionality. Therefore, differences in the functional networks between PDA patients and control subjects should be further investigated."],["dc.identifier.doi","10.1007/s00406-015-0653-6"],["dc.identifier.fs","624606"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/10614"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","904"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","913"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Weiss, Nina"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Neubert, Karin"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T08:38:05Z"],["dc.date.available","2018-11-07T08:38:05Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives. Regular aerobic exercise (running) has been shown to be superior to a pill placebo in the treatment of panic disorder. Combined drug and exercise treatment has not been investigated in randomized controlled studies to date. Methods. This is a randomized, 10-week, controlled, parallel group, pilot study. A total of 75 outpatients with panic disorder with or without agoraphobia (DSM-IV and ICD-10) received either (1) exercise plus paroxetine 40 mg/day (n = 21), (2) relaxation plus paroxetine (n = 17), (3) exercise plus pill placebo (n = 20), or (4) relaxation plus pill placebo (n = 17). Changes in the Panic and Agoraphobia Scale (P&A), and the Clinical Global Impression Scale (CGI) underwent repeated measure analysis. Results. Effects sizes were large for all groups (d = 1.53-3.87), however not significantly different. Paroxetine-treated patients were significantly more improved than placebo-treated patients. On the CGI, patients in the exercise groups (plus paroxetine or placebo) had a trend toward better improvement compared to relaxation (P = 0.06). Response and remission rates were higher in the paroxetine compared to pill placebo groups. Conclusions. While paroxetine was superior to placebo, aerobic exercise did not differ from relaxation training in most efficacy measures."],["dc.description.sponsorship","GlaxoSmithKline"],["dc.identifier.doi","10.3109/15622975.2010.489620"],["dc.identifier.isi","000282191400008"],["dc.identifier.pmid","20602575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18686"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1562-2975"],["dc.title","A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","173"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Medical Microbiology and Immunology"],["dc.bibliographiccitation.lastpage","180"],["dc.bibliographiccitation.volume","193"],["dc.contributor.author","Sindermann, H."],["dc.contributor.author","Croft, S. L."],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Bommer, W."],["dc.contributor.author","Eibl, Hans-Joerg"],["dc.contributor.author","Unger, C."],["dc.contributor.author","Engel, J."],["dc.date.accessioned","2018-11-07T10:44:24Z"],["dc.date.available","2018-11-07T10:44:24Z"],["dc.date.issued","2004"],["dc.description.abstract","Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy."],["dc.identifier.doi","10.1007/s00430-003-0201-2"],["dc.identifier.isi","000225206800003"],["dc.identifier.pmid","14513375"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47259"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0300-8584"],["dc.title","Miltefosine (Impavido): the first oral treatment against leishmaniasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1520"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Clinical Infectious Diseases"],["dc.bibliographiccitation.lastpage","1523"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Sindermann, H."],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Fischer, C."],["dc.contributor.author","Bommer, W."],["dc.date.accessioned","2018-11-07T10:43:55Z"],["dc.date.available","2018-11-07T10:43:55Z"],["dc.date.issued","2004"],["dc.description.abstract","Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes."],["dc.identifier.doi","10.1086/425359"],["dc.identifier.isi","000227492000019"],["dc.identifier.pmid","15546090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47155"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1058-4838"],["dc.title","Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Obst, Katrin U."],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Ulrich, Kalinke"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T09:01:15Z"],["dc.date.available","2018-11-07T09:01:15Z"],["dc.date.issued","2011"],["dc.identifier.isi","000208641302154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24376"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.publisher.place","Paris"],["dc.relation.issn","0924-9338"],["dc.title","FUNCTIONAL MRI ACTIVATION IN RESPONSE TO PANIC-SPECIFIC, NON-PANIC AVERSIVE, AND NEUTRAL IMAGERY IN PATIENTS WITH PANIC DISORDER AND HEALTHY CONTROLS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5638"],["dc.bibliographiccitation.issue","35"],["dc.bibliographiccitation.journal","Current Pharmaceutical Design"],["dc.bibliographiccitation.lastpage","5644"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Neumann, Charlott"],["dc.contributor.author","Obst, Katrin"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2021-06-01T10:48:34Z"],["dc.date.available","2021-06-01T10:48:34Z"],["dc.date.issued","2012"],["dc.description.abstract","Visual emotional stimulation is supposed to elicit psycho-vegetative reactions, which are similar to as the ones elicited by exposure to actual experience. Visual stimulation paradigms have been widely used in studies on agoraphobia with and without panic disorder. However, the applied imagery has hardly ever been disorder-and subject-specific. 51 patients with an ICD-10 and DSM-IV diagnosis of agoraphobia with or without panic disorder (PDA) and matching healthy controls have been examined. Subjects were confronted with 146 picture showing characteristic agoraphobic situations (high places, narrow places, crowds, public transport facilities, or wide places) or pictures associated with acute physical emergency (panic) situations, which had been pre-selected by anxiety experts. Participants were asked to rate emotional arousal induced by the respective images on the Self-Assessment Manikin scale (SAM). Data on PDA severity (PAS) depressive symptoms (MADRS) and sociodemographic data were recorded. Saliva cortisol levels were measured before and after exposure in a second test applying the individually mostly feared stimuli combined with emotionally neutral pictures for every single patient. 117 of the PDA-specific images were rated significantly more fear-eliciting by patients than by healthy individuals. Sub-categorization into agoraphobia clusters showed differential effects of clusters with regard to gender distribution, severity of PDA and cortisol secretion during exposure. In this study disorder specific and individual characteristics of agoraphobia were assessed for use in future trials applying emotional imagery. It could be used for the differential assessment of PDA and associated neurobiological and psychological phenomena and in neuroimaging paradigms."],["dc.identifier.doi","10.2174/138161212803530862"],["dc.identifier.isi","000309968500005"],["dc.identifier.pmid","22632470"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85983"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1381-6128"],["dc.title","Disorder-Specific Emotional Imagery for Differential and Quantitative Assessment of Agoraphobia"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","24"],["dc.bibliographiccitation.journal","Wiener klinische Wochenschrift"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Bommer, W."],["dc.contributor.author","Eibl, Hans-Joerg"],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Kuhlencord, A."],["dc.contributor.author","Sindermann, H."],["dc.contributor.author","Sundar, S."],["dc.contributor.author","Zappel, H."],["dc.date.accessioned","2018-11-07T10:53:18Z"],["dc.date.available","2018-11-07T10:53:18Z"],["dc.date.issued","2004"],["dc.description.abstract","Hexadecylphosphocholine (HDPC, Miltefosine, Impavido(R)) was synthesized at the Max-Planck-Institut fir Biophysikalische Chemie in Gottingen, Germany and successfully used for the therapy of cancer metastases [7, 8]. At the Institute of General and Tropical Hygiene of Gottingen University the antiparasitic efficacy - earlier mentioned by Croft et al. (1987) [6] - could be established for the first time in animals after oral administration [14]. In India Impavido(R) has been recently registered for the treatment of visceral leishmaniasis as the first oral medication in this indication. Clinical studies in India [13,17-19] - actually a phase IV study is running and Columbia (cutaneous leishmaniosis [15]) demonstrated the excellent efficacy of this oral treatment also in patients with Antimon resistance [9-11]. The cure rates are above 90% with low side effects (Impavido(R) twice 50 mg capsules daily over 28 days)."],["dc.identifier.isi","000226528800005"],["dc.identifier.pmid","15683039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49328"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.conference","37th Annual Meeting of the Austrian-Society-for-Tropical-Medicine-and-Parasitolgy"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","1613-7671"],["dc.relation.issn","0043-5325"],["dc.title","Leishmaniasis - Oral treatment with hexadecylphosphocholine"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","285"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","294"],["dc.bibliographiccitation.volume","269"],["dc.contributor.author","Uhlmann, A."],["dc.contributor.author","Bandelow, B."],["dc.contributor.author","Stein, D. J."],["dc.contributor.author","Bloch, S."],["dc.contributor.author","Engel, K. R."],["dc.contributor.author","Havemann-Reinecke, U."],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2020-12-10T14:10:30Z"],["dc.date.available","2020-12-10T14:10:30Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00406-018-0870-x"],["dc.identifier.eissn","1433-8491"],["dc.identifier.issn","0940-1334"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70783"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety—an MRI study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]